UBS: Lilly’s $3.25B Kelonia Acquisition Expands Next-Gen CAR-T Pipeline
UBS says Lilly’s $3.25B Kelonia buy boosts its next-generation CAR-T pipeline by adding a Phase I in vivo BCMA therapy that achieved MRD-negative responses in all four patients with five-month durability. They note the off-the-shelf lentiviral platform showed no high-grade cytokine release syndrome or neurotoxicity, differentiating it from rival CAR-T therapies.
1. Deal Overview
Lilly agreed to acquire Kelonia Therapeutics for $3.25 billion, marking one of the largest deals in the in vivo CAR-T sector. This transaction adds an early-stage program to Lilly’s pipeline as it seeks growth beyond its established GLP-1 franchise.
2. Early Clinical Results
Kelonia’s lead asset is a Phase I in vivo BCMA-targeted CAR-T therapy for multiple myeloma. Early data from four patients showed MRD-negative responses in all treated individuals, with the longest follow-up demonstrating durable responses at five months.
3. Platform and Safety Profile
The therapy uses an off-the-shelf lentiviral delivery system that bypasses lymphodepleting chemotherapy. Initial safety findings reported no high-grade cytokine release syndrome, neurotoxicity or other severe adverse events, suggesting a favorable risk profile.
4. Strategic Implications
UBS analysts view this acquisition as a constructive move to diversify Lilly’s cell therapy offerings and deepen its presence in next-generation CAR-T. They believe the differentiated platform and early safety data could position Lilly ahead of competitors in the emerging in vivo CAR-T market.